Lysosomal storage disorders: The need for better pediatric recognition and comprehensive care

Journal of Pediatrics

Volumn 144, Issue 5 SUPPL., 2004, Pages

  Wilcox, William R ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALGLUCERASE; ALPHA GALACTOSIDASE; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME; GLUCOSIDASE; GLUCOSYLCERAMIDASE; IMIGLUCERASE; LARONIDASE; LEVO IDURONIDASE; LOPERAMIDE; MELATONIN; MERCAPTAMINE; MIGLUSTAT; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHONIC ACID DERIVATIVE;

BEHAVIOR DISORDER; BONE MARROW TRANSPLANTATION; CARPAL TUNNEL SYNDROME; CATARACT; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CORNEA DISEASE; CYSTINOSIS; DEPRESSION; DIARRHEA; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG HYPERSENSITIVITY; DYSARTHRIA; ENZYME REPLACEMENT; FABRY DISEASE; GASTROINTESTINAL DISEASE; GAUCHER DISEASE; GENE THERAPY; GLAUCOMA; GLOBOID CELL LEUKODYSTROPHY; GLYCOGEN STORAGE DISEASE TYPE 2; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEART ARRHYTHMIA; HEMANGIOKERATOMA; HEMATOLOGIC DISEASE; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; HYDROCEPHALUS; KIDNEY FAILURE; KIDNEY TUBULE DISORDER; LYSOSOME; LYSOSOME STORAGE DISEASE; MALNUTRITION; MANNOSIDOSIS; MAROTEAUX LAMY SYNDROME; METACHROMATIC LEUKODYSTROPHY; MORQUIO SYNDROME; MUCOLIPIDOSIS; MUSCULOSKELETAL DISEASE; NEPHROSIS; NEUROPATHIC PAIN; NIEMANN PICK DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; SANFILIPPO SYNDROME; SEIZURE; SIALIC ACID STORAGE DISEASE; SIDE EFFECT; SLEEP APNEA SYNDROME; SLEEP DISORDER; SPINAL CORD COMPRESSION; TAY SACHS DISEASE; VALVULAR HEART DISEASE; WOLMAN DISEASE;

EID: 2342502654     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2004.01.049     Document Type: Conference Paper

References (66)

1. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of sosomal storage disorders. JAMA 1999;281:249-54.
2. Poorthuis BJ, Wevers RA, Kleijer WJ, Greener JE, de Jong JG, van Weely S, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999;105:151-6.
3. Sugie K, Yamamoto A, Murayama K, Oh SJ, Takahashi M, Mora M, et al. Clinicopathological features of genetically confirmed Danon disease. Neurology 2002;58:1773-8.
4. Nishino I, Fu J, Tanji K, Yamada T, Shimojo S, Koori T, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000;406:906-10.
5. Aula P, Renlund M, Raivio KO, Koskela SL. Screening of inherited oligosaccharidurias among mentally retarded patients in northern Finland. J Ment Defic Res 1986;30(Pt 4):365-8.
6. Mononen T, Mononen I, Matilainen R, Airaksinen E. High prevalence of aspartylglycosaminuria among school-age children in eastern Finland. Hum Genet 1991;87:266-8.
7. Mistry PK. Gaucher's disease: a model for modern management of a genetic disease. J Hepatol 1999;30 Suppl 1:1-5.
8. Natowicz MR, Prence EM. Heterozygote screening for Tay-Sachs disease: past successes and future challenges. Curr Opin Pediatr 1996;8:625-9.
9. Schuchman EH, Miranda SR. Niemann-Pick disease: mutation update, genotype/phenotype correlations, and prospects for genetic testing. Genet Test 1997;1:13-9.
10. Edelmann L, Dong J, Desnick RJ, Kornreich R. Carrier screening for mucolipidosis type IV in the American Ashkenazi Jewish population. Am J Hum Genet 2002;70:1023-7.
11. Voskoboeva EY, Krasnopolskaya XD, Mirenburg TV, Weber B, Hopwood JJ. Molecular genetics of mucopolysaccharidosis type I: mutation analysis among the patients of the former Soviet Union. Mol Genet Metab 1998;65:174-80.
12. Koprivica V, Stone DL, Park JK, Callahan M, Frisch A, Cohen IJ, et al. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet 2000;66:1777-86.
13. de Duve C, Pressman B, Gianetto R, Wattiaux R, Appelmans F. Tissue fractionation studies. Intracellular distribution patterns of enzymes in rat liver. Biochem J 1955;60:604.
14. Beck M. Variable clinical presentation in lysosomal storage disorders. J Inherit Metab Dis 2001;24 Suppl 2:47-51; discussion 45-6.
15. Clarke LA. Clinical diagnosis of lysosomal storage diseases. In: Applegarth D, Dimmick JE, Hall JG, eds. Organelle diseases. London: Chapman and Hall; 1997. p. 37-71.
16. Grabowski G. Lysosomal storage diseases. In: Braunwald E, Fauci AS, Kasper DL, et al, eds. Harrison's principles of internal medicine. 15th ed. New York: McGraw Hill; 2001. p. 2276-81.
17. Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. Metabolic and molecular bases of inherited disease. New York: McGraw Hill; 2001. p. 3733-74.
18. Grabowski G, Beutler E. Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. Metabolic and molecular bases of inherited disease. New York: McGraw Hill; 2001. p. 3635-68.
19. Lake BD, Young EP, Winchester BG. Prenatal diagnosis of lysosomal storage diseases. Brain Pathol 1998;8:133-49.
20. Meikle PJ, Ranieri E, Ravenscroft EM, Hua CT, Brooks DA, Hopwood JJ. Newborn screening for lysosomal storage disorders. Southeast Asian J Trop Med Public Health 1999;30 Suppl 2:104-10.
21. Ranierri E, Gerace RL, Ravenscroft EM, Hopwood JJ, Meikle PJ. Pilot neonatal screening program for lysosomal storage disorders, using lamp-1. Southeast Asian J Trop Med Public Health 1999;30 Suppl 2:111-3.
22. Becker MH, Kaback MM, Rosenstock IM, Ruth MV. Some influences on public participation in a genetic screening program. J Commun Health 1975;1:3-14.
23. Zinberg RE, Kornreich R, Edelmann L, Desnick RJ. Prenatal genetic screening in the Ashkenazi Jewish population. Clin Perinatol 2001;28:367-82.
24. Peters C, Balthazor M, Shapiro EG, King RJ, Kollman C, Hegland JD, et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996;87:4894-902.
25. Guffon N, Souillet G, Maire I, Straczek J, Guibaud P. Follow-up of nine patients with Hurler syndrome after bone marrow transplantation. J Pediatr 1998;133:119-25.
26. Hite SH, Peters C, Krivit W. Correction of odontoid dysplasia following bone-marrow transplantation and engraftment (in Hurler syndrome MPS 1H). Pediatr Radiol 2000;30:464-70.
27. Kachur E, Del Maestro R. Mucopolysaccharidoses and spinal cord compression: case report and review of the literature with implications of bone marrow transplantation. Neurosurgery 2000;47:223-228; discussion 8-9.
28. Hoogerbrugge PM, Brouwer OF, Bordigoni P, Ringden O, Kapaun P, Ortega JJ, et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet 1995;345:1398-402.
29. Vellodi A, Young E, Cooper A, Lidchi V, Winchester B, Wraith JE. Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 1999;22:638-48.
30. Herskhovitz E, Young E, Rainer J, Hall CM, Lidchi V, Chong K, et al. Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow-up. J Inherit Metab Dis 1999;22:50-62.
31. Wall DA, Grange DK, Goulding P, Daines M, Luisiri A, Kotagal S. Bone marrow transplantation for the treatment of alpha-mannosidosis. J Pediatr 1998;133:282-5.
32. Krivit W, Peters C, Dusenbery K, Ben-Yoseph Y, Ramsay NK, Wagner JE, et al. Wolman disease successfully treated by bone marrow transplantation. Bone Marrow Transplant 2000;26:567-70.
33. Krivit W, Shapiro E, Kennedy W, Lipton M, Lockman L, Smith S, et al. Treatment of late infantile metachromatic leukodystrophy by bone marrow transplantation. N Engl J Med 1990;322:28-32.
34. Krivit W, Peters C, Shapiro EG. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol 1999;12:167-76.
35. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344:182-8.
36. Van den Hout JM, Reuser AJ, de Klerk JB, Arts WF, Smeitink JA, Van der Ploeg AT. Enzyme therapy for Pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis 2001;24:266-74.
37. Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001;3:132-8.
38. Kishnani P, Voit T, Nicolino M, Amalfitano A, Tsai CH, Herman G, et al. Recombinant human acid alpha glucosidase (rhGAA) for treatment of classical infantile Pompe disease (CIPD): preliminary data from a phase 2 study. [abstract]. J Inherit Metab Dis 2002;25 Suppl 1:234-40.
39. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991;324:1464-70.
40. Grabowski GA, Leslie N, Wenstrup R. Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev 1998;12:115-33.
41. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112-9.
42. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16.
43. Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-9.
44. Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001;68:711-22.
45. Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M, et al. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 2000;97:365-70.
46. Clarke L, Muenzer J, Kolodny EH, Pastores G, Beck M, Wraith JE. RhIDU enzyme replacement therapy for MPS I:24 week extension study. Am J Hum Genet 2002;71 Suppl:481.
47. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A: safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993;328:453-9.
48. Goodeve AC, Williams I, Bray GL, Peake IR. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group. Thromb Haemost 2000;83:844-8.
49. Ponce E, Moskovitz J, Grabowski G. Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase. Blood 1997;90:43-8.
50. Brady RO, Murray GJ, Oliver KL, Leitman SF, Sneller MC, Fleisher TA, et al. Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease. Pediatrics 1997;100:E11.
51. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998;42:1083-1099; discussion 99-100.
52. Gahl WA, Thoene JG, Schneider JA, O'Regan S, Kaiser-Kupfer MI, Kuwabara T. NIH conference: cystinosis: progress in a prototypic disease. Ann Intern Med 1988;109:557-69.
53. Schneider JA, Clark KF, Greene AA, Reisch JS, Markello TC, Gahl WA, et al. Recent advances in the treatment of cystinosis. J Inherit Metab Dis 1995;18:387-97.
54. Platt FM, Jeyakumar M, Andersson U, Priestman DA, Dwek RA, Butters TD, et al. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J Inherit Metab Dis 2001;24:275-90.
55. Tifft CJ, Proia RL. Stemming the tide: glycosphingolipid synthesis inhibitors as therapy for storage diseases. Glycobiology 2000;10:1249-58.
56. Lachmann RH, Platt FM. Substrate reduction therapy for glycosphingolipid storage disorders. Expert Opin Investig Drugs 2001;10:455-66.
57. Frustaci A, Chimenti C, Ricci R, Natale L, Russo MA, Pieroni M, et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 2001;345:25-32.
58. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000;355:1481-5.
59. Balicki D, Beutler E. Gene therapy of human disease. Medicine (Baltimore) 2002;81:69-86.
60. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao G, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80:148-58.
61. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002;346:1185-93.
62. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000;288:669-72.
63. Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 2003;3:477-88.
64. Poenaru L. From gene transfer to gene therapy in lysosomal storage diseases affecting the central nervous system. Ann Med 2001;33:28-36.
65. Yew NS, Cheng SH. Gene therapy for lysosomal storage disorders. Curr Opin Mol Ther 2001;3:399-406.
66. Dunbar CE, Kohn DB, Schiffmann R, Barton NW, Nolta JA, Esplin JA, et al. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum Gene Ther 1998;9:2629-40.